Pharsight

Restasis Multidose patents expiration

RESTASIS MULTIDOSE's oppositions filed in EPO
RESTASIS MULTIDOSE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8648048 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(3 months from now)

US8633162 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(3 months from now)

US9248191 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(3 months from now)

US8629111 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(3 months from now)

US8685930 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(3 months from now)

US8642556 ABBVIE Methods of providing therapeutic effects using cyclosporin components
Aug, 2024

(3 months from now)

US8292129 ABBVIE Dispensing device
Feb, 2031

(6 years from now)

US8561859 ABBVIE Dispensing device
Apr, 2032

(7 years from now)

US9676525 ABBVIE Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
Feb, 2034

(9 years from now)

US9669974 ABBVIE Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids
May, 2034

(9 years from now)

Restasis Multidose is owned by Abbvie.

Restasis Multidose contains Cyclosporine.

Restasis Multidose has a total of 10 drug patents out of which 0 drug patents have expired.

Restasis Multidose was authorised for market use on 23 December, 2002.

Restasis Multidose is available in emulsion;ophthalmic dosage forms.

Restasis Multidose can be used as increase tear production to treat patients with keratoconjunctivitis sicca (dry eye)., increase tear production in patients with keratoconjunctivitis sicca (dry eye)..

The generics of Restasis Multidose are possible to be released after 11 May, 2034.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CYCLOSPORINE ingredient

Market Authorisation Date: 23 December, 2002

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

How can I launch a generic of RESTASIS MULTIDOSE before it's drug patent expiration?
More Information on Dosage

RESTASIS MULTIDOSE family patents

Family Patents